ArticleLeukemia2024
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shai Shimony et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
25 papers cite it
this paperpooled ittrialcites it